[{"uuid": "b93b6dee-f1f7-39c9-af8b-ef27e3496667", "title": "Wall Street Analysts Predict a 27.12% Upside in Amneal (AMRX): Here's  What You Should Know", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/wall-street-analysts-predict-27-145507287.html", "providerPublishTime": 1738594507, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a", "width": 900, "height": 476, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pdW5wHTIEKqiEK3RrmtVaw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "0988c8a9-95f7-3684-a988-e9bc85268121", "title": "Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/zacks-industry-outlook-highlights-corcept-090900450.html", "providerPublishTime": 1738573740, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/KEj1lCkxRqndrrMrF3m.HA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/L9oXp_PBujUXs0r0RIkKrg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9c7450ec9df154559fbeb393640d6629", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DYN", "^GSPC", "NKTR", "CORT"]}, {"uuid": "a5f26469-6401-3865-8abd-a54714f7d0cf", "title": "5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/5-small-drug-stocks-add-130300236.html", "providerPublishTime": 1738328580, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HNGK8KXbnuM7D3xIxBkleg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/z7kgzqHlPiCBk2zPji8Otw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CORT", "DYN", "^GSPC", "NKTR"]}, {"uuid": "f4d0bbf1-7fe6-325e-800a-b1670ef55df2", "title": "7MM PD market to grow by $4.5bn between 2023 and 2033", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/f4d0bbf1-7fe6-325e-800a-b1670ef55df2/7mm-pd-market-to-grow-by.html", "providerPublishTime": 1738236179, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/eU_rGTgDDv_d6.HjhFcjAA--~B/aD00MjA7dz04NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/653e3fbaf8ba66c0170d04f6e1976783", "width": 840, "height": 420, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Fc2L3yD.y7TM5Hjx2fEGJw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/653e3fbaf8ba66c0170d04f6e1976783", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMRX", "ACHC", "SUPN"]}, {"uuid": "3eea1ec1-b014-3a63-9cc4-a534b25f0329", "title": "Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amneal-report-fourth-quarter-full-133000411.html", "providerPublishTime": 1738157400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0eyvE5_cx.LUsFGDm4FV5A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/366d10a0f40f8e8829fc7bf5b12beea1", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/unDIyJ5_ZFYpY3x_T0EG1w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/366d10a0f40f8e8829fc7bf5b12beea1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMRX"]}, {"uuid": "5db19f6d-9fa6-3be9-9b84-269682fe1869", "title": "Kashiv Biosciences\u2019 Phase I trial of KSHB002 injection meets primary endpoints", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/5db19f6d-9fa6-3be9-9b84-269682fe1869/kashiv-biosciences%E2%80%99-phase-i.html", "providerPublishTime": 1738153519, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/BonpMGM6qivV0vBZreNY0A--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/59a899fcac036a932f728cc91aea2c40", "width": 1440, "height": 810, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/rTax1YD8F3oJayPSBvPvpQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/59a899fcac036a932f728cc91aea2c40", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMRX"]}, {"uuid": "4b7e59dc-d319-3981-9f7c-26aeab3acfbf", "title": "Amneal Pharmaceuticals Gets US FDA Approvals for Alzheimer's, Oncology Treatments, Gastrointestinal Disease", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/amneal-pharmaceuticals-gets-us-fda-143119206.html", "providerPublishTime": 1737642679, "type": "STORY"}, {"uuid": "3aed8d7f-e475-3bc3-a478-b424b325b6da", "title": "Corcept Therapeutics Incorporated (CORT) Hit a 52 Week High, Can the Run Continue?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/corcept-therapeutics-incorporated-cort-hit-141503997.html", "providerPublishTime": 1737728103, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/AwCmIhR0z9Bg4cEkwuNQjw--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n4.AbgyuCxTPgpWcYEizKw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CORT"]}, {"uuid": "382eb1bc-3540-3864-a592-276bbae3c312", "title": "Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/amneal-receives-u-fda-approval-130000700.html", "providerPublishTime": 1737637200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Q2AA2vRvHbqzZkvzRVwZ9A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2849214be3fad47437fe7abcf1bdb300", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/GE0ZzxIwAgP6WHrfVqA4Jg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2849214be3fad47437fe7abcf1bdb300", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMRX"]}, {"uuid": "0c8ff228-f30c-350b-9bfe-952665c74e88", "title": "Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/amneal-pharmaceuticals-amrx-stock-outpacing-144009390.html", "providerPublishTime": 1737038409, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/t6.OdXEVKQihFo9otNenfg--~B/aD01NjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9", "width": 900, "height": 565, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/k5cTNiJKtV5aggvBgwLXAQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/4f1a8d86cead9f96536efb147945dcc9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AVAH"]}, {"uuid": "b16be85d-3654-3142-8aff-8ae093d5531a", "title": "Amneal (AMRX) Upgraded to Strong Buy: Here's Why", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/amneal-amrx-upgraded-strong-buy-170013365.html", "providerPublishTime": 1736355613, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0", "width": 900, "height": 601, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/8iH7sUYRxbYanfZU7fLgpA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "62ecdf79-5090-38db-96b8-9412e4443619", "title": "Here\u2019s Why Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Is Among the Best Diabetes Stocks to Buy Under $10", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-amneal-pharmaceuticals-inc-nasdaq-134518326.html", "providerPublishTime": 1736171118, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/1MWu7WRn.oY6cG7sNz4UXg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/34e5f9b043b3d4fdd58d90d8c07a5bc6", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/YJSA1xyF6AcNlHDllFoqtw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/34e5f9b043b3d4fdd58d90d8c07a5bc6", "width": 140, "height": 140, "tag": "140x140"}]}}]